Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also ...

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 ...

ACA marketplace premiums are projected to rise by 26% in 2026, with potential further increases if premium tax credits expire ...

Over the past generation, advances in treating common cancers—breast, lung, melanoma, and gastrointestinal (GI)—have improved ...

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...

Value-based oncology care requires balancing rapid innovation with operational sustainability, equitable access, and ...

It is necessary to balance rigorous clinical trials with real-world evidence (RWE) to show how data from everyday practice ...

Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...